Agilent expands collaboration with C‑CAMP to scale access to advanced life sciences analytics across India

IMT News Desk
IMT News Desk
· 2 min read
Agilent and C-CAMP have announced a strategic collaboration to strengthen life sciences and therapeutic research across India

Agilent Technologies has announced an expansion of its collaboration with the Centre for Cellular and Molecular Platforms (C‑CAMP), a Department of Biotechnology-supported initiative. It broadens access to advanced analytical and mass spectrometry‑based capabilities that support life sciences and therapeutic research across India.

Through this collaboration, high‑resolution analytical platforms will be made available via C‑CAMP’s shared infrastructure, supporting applications such as biotherapeutic characterization, oligonucleotide research and quantitative biomolecular analysis.

This model is designed to enable researchers from startups, academia and industry to access advanced analytical workflows and deep domain expertise without the need for direct capital investment in specialized instruments or facilities.

Agilent’s collaboration with C‑CAMP has played a catalytic role in advancing India’s biopharma ecosystem by enabling world‑class, regulatory‑aligned characterization of biologics and biosimilars across therapeutic applications.

The engagement aligns with C‑CAMP’s vision towards building a connected ecosystem that supports science‑to‑impact pathways, while leveraging Agilent’s expertise in analytical workflows and technology enablement.

“India is a strategic priority for Agilent and partnerships like this are central to how we expand access to critical scientific capabilities,” said Nandakumar Kalathil, Country General Manager, Agilent India. “Working with C‑CAMP allows a broader community of researchers to leverage advanced analytical workflows that support high‑quality, reproducible science across discovery and translational research.”

“Across Asia Pacific, we are seeing a strong shift toward collaborative, shared infrastructure models that enable broader participation in advanced scientific research,” said Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies. “Our expanded engagement with C CAMP reflects Agilent’s commitment to building inclusive innovation ecosystems where startups, academia and industry can accelerate high-quality research and translate science into meaningful impact.”

 “Partnerships with frontier science and technology leaders such as Agilent will help C-CAMP build cutting-edge capabilities in India to support researchers and innovators across the country. In the coming years, we believe such collaborations will play a key role in enabling technology development and accelerating science-led innovation,” said Dr Taslimarif Saiyed, Director and CEO, CCAMP. “The engagement also aligns with C-CAMP’s vision of building a connected ecosystem that supports science-to-impact pathways, while leveraging Agilent’s expertise in analytical workflows and technology enablement.”

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk